ASH 2018 | Long-term follow-up of acalabrutinib in R/R mantle cell lymphoma
In this interview, Simon Rule, MD, of Plymouth University, Plymouth, UK, discusses the long-term (over 24 months) follow-up of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL) from the ACE-LY-004 study (NCT02213926). Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Rule presents the promising data, which not only confirms the efficacy and durable response rate from single-agent acalabrutinib, but also show limited additional safety signals.
